Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Diabetes and obesity treatment based on dual incretin receptor activation: twincretins
Proven results backed by scientific studies
UK delivery is 4.50 by Royal Mail Tracked 24, or free once your basket reaches 45 (29.01 away at this price)
ATTAIN-1 (NCT05869903) The key trial for the obesity indication, ATTAIN-1 randomized 3,127 adults with obesity or overweight (without diabetes) to orforglipron 6 mg, 12 mg, or 36 mg versus placebo for 72 weeks
Lancet 2008
doi:10.1016/S0090-9556(24)15356-1
US$ 21.34
US$ 26.83
US$ 20.74
